EPS společnosti Shanghai Junshi Biosciences Co
Jaká je hodnota metriky EPS společnosti Shanghai Junshi Biosciences Co?
Hodnota metriky EPS společnosti Shanghai Junshi Biosciences Co., Ltd. je -0.44
Jaká je definice metriky EPS?
Zisk na akcii (Eearnings per share - EPS) je zisk společnosti na jednu akcii. Bere v úvahu ředění akcií a počítá se za posledních dvanáct měsíců.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
EPS společností v sektoru Health Care sektor na OTC ve srovnání se společností Shanghai Junshi Biosciences Co
Čemu se věnuje společnost Shanghai Junshi Biosciences Co?
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Firmy s metrikou eps podobnou společnosti Shanghai Junshi Biosciences Co
- Hodnota metriky EPS společnosti Openpay Ltd je -0.45
- Hodnota metriky EPS společnosti Atrium European Real Estate je -0.45
- Hodnota metriky EPS společnosti AudioValley SA je -0.45
- Hodnota metriky EPS společnosti Parity plc je -0.44
- Hodnota metriky EPS společnosti Proseed India je -0.44
- Hodnota metriky EPS společnosti Gordon Pointe Acquisition je -0.44
- Hodnota metriky EPS společnosti Shanghai Junshi Biosciences Co je -0.44
- Hodnota metriky EPS společnosti Titan Medical je -0.44
- Hodnota metriky EPS společnosti Aurania Resources je -0.44
- Hodnota metriky EPS společnosti Clarivate Plc je -0.44
- Hodnota metriky EPS společnosti Shenwan Hongyuan (H.K.) je -0.44
- Hodnota metriky EPS společnosti Lanzhou Zhuangyuan Pasture Co je -0.44
- Hodnota metriky EPS společnosti UCloud Technology Co je -0.44